Lead Plaintiff Deadline: September 23, 2019
See If You Qualify For Monetary Reward
Please Upload related files below
Fill in below.
Looking for more?
Throughout the Class Period, the Company continued to tout the commercial prospects for selinexor and consistently described selinexor as having a “predictable and manageable tolerability profile” and a “very nice safety profile,” and assured investors that it was “well tolerated” by patients. Karyopharm also claimed that selinexor had the potential to be used as a new treatment for MM, with limited and manageable side effects. As a result of these misrepresentations, Karyopharm shares traded at artificially inflated prices during the Class Period.
In order to be included in the lawsuit, you must have incurred a loss on shares of purchased or acquired during the class period listed above.
If you suffered a loss in during the relevant time frame, you have until September 23, 2019 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.